Nantkwest / Immunitybio -> IBRX WKN: A2QQ2E ISIN: US45256X1037 Forum: Aktien User: captainpump97

Welcome Back - ich hab nach dir gefragt

LEUTE GLÜCKWUNSCH AN ALLE - ich freue mich wie Sau 😍😍😍😍😍

ICH HABS EINFACH VERPASST - no wayyyyyy

JAAAAAAAAAA

OMFG

Der verlorene Sohn 😂 Welcome back 😁

und ich hab's verpasst 😱

YESSSSSS 🥳

😊

Kann ich die Börsenöffnung kauf erwarten… hoffen wir mal der Pump kommt

Danke Jungs und Mädels für die Updates in der Nacht!!! ❤️

Jaaaaaaaaaaaaaaaaaaaaaaaaaaa

Jabadabadooooooooo :) 🥳

Guten Morgen - wars der Vollmond oder warum hab ich so unruhig geschlafen- - nachbörslich + 22 % -

U.S. FDA approves ImmunityBio's bladder cancer therapy The U.S. health regulator on Monday approved ImmunityBio's (IBRX.O), opens new tab combination therapy to treat a type of bladder cancer, marking an end to the company's efforts to bring its therapy to the market. The agency's green light is a shot in the arm for ImmunityBio, which had reiterated doubts in a regulatory filing, opens new tab last month about its ability to remain in business. Last year, the U.S. Food and Drug Administration declined clearance for the therapy, Anktiva, over deficiencies found during pre-license inspection of the company's contract manufacturing firms. The therapy works by activating types of disease fighting white blood cells called natural killer (NK) cells and T-cells to create long-term immunity in the body. The company did not immediately respond to a request seeking details on the therapy's label, availability and pricing. ImmunityBio's drug is used in combination with the Bacillus Calmette-Guérin (BCG) vaccine, which is mainly used against tuberculosis, but also as a common treatment for some forms of bladder cancer. https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-immunitybios-bladder-cancer-therapy-2024-04-22/

 Reuters23.04.2024 00:25 Folgen IBRX -6,26 % 22. April (Reuters) – Die US-amerikanische Arzneimittelbehörde FDA hat die IBRX.O-Kombinationstherapie von ImmunityBio zur Behandlung einer Art von Blasenkrebs zugelassen, teilte die Aufsichtsbehörde am Montag mit, was dazu beitragen würde, das erste Produkt des Unternehmens auf den Markt zu bringen